Tiotropium mist (Respimat) increases mortality risk, authors say - PulmCCM
Advertisement
Jun 112011
 

Singh et al analyzed 5 randomized trials comparing tiotropium mist to placebo, and found a 46% relative increased risk of all-cause mortality among the treated arms. The Respimat inhaler is available in Europe, but the FDA has not approved it in the US. BMJ 2011;342:d3215.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of pulmonary and critical care guidelines, practice updates and review articles.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society and/or journal referenced on the website.

Leave a Comment